G. Pentheroudakis

3.6k total citations · 3 hit papers
33 papers, 2.2k citations indexed

About

G. Pentheroudakis is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, G. Pentheroudakis has authored 33 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in G. Pentheroudakis's work include Colorectal Cancer Treatments and Studies (6 papers), Economic and Financial Impacts of Cancer (4 papers) and Cancer Risks and Factors (3 papers). G. Pentheroudakis is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Economic and Financial Impacts of Cancer (4 papers) and Cancer Risks and Factors (3 papers). G. Pentheroudakis collaborates with scholars based in Greece, United Kingdom and Spain. G. Pentheroudakis's co-authors include Nicholas Pavlidis, Axel Hauschild, Reinhard Dummer, Merlin Guggenheim, Hatem A. Azim, Vesna Kesić, Roberto Orecchia, Harald J. Hoekstra, Fedro A. Peccatori and Josep Tabernero and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

G. Pentheroudakis

32 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2012 582 citations Reinhard Dummer, Axel Hauschild et al. Annals of Oncology profile →
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2013 528 citations Fedro A. Peccatori, Hatem A. Azim et al. Annals of Oncology profile →
ESMO-Magnitude of Clinical Benefit Scale version 1.1

2017 369 citations Nathan I. Cherny, Urania Dafni et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Pentheroudakis Greece	14	1.3k	500	411	384	331	33	2.2k
Maria Carmela Piccirillo Italy	26	1.2k 0.9×	502 1.0×	787 1.9×	408 1.1×	223 0.7×	94	2.3k
Sidney Scudder United States	20	603 0.5×	406 0.8×	316 0.8×	286 0.7×	281 0.8×	49	1.9k
Wendi Qian United Kingdom	26	2.3k 1.7×	515 1.0×	763 1.9×	636 1.7×	323 1.0×	82	4.3k
Luigi Manzione Italy	29	2.4k 1.9×	386 0.8×	1.3k 3.1×	394 1.0×	637 1.9×	88	3.4k
RD Gelber Switzerland	17	1.7k 1.3×	485 1.0×	502 1.2×	909 2.4×	243 0.7×	37	2.7k
Audrey Mauguen United States	27	785 0.6×	406 0.8×	509 1.2×	321 0.8×	185 0.6×	111	2.1k
Vernon Harvey New Zealand	22	1.3k 1.0×	258 0.5×	357 0.9×	489 1.3×	107 0.3×	44	1.8k
Anne Floquet France	30	1.3k 1.0×	442 0.9×	758 1.8×	521 1.4×	665 2.0×	170	3.3k
Steven J. Lemery United States	26	1.8k 1.4×	545 1.1×	852 2.1×	782 2.0×	482 1.5×	65	3.3k
Steve Dahlberg United States	22	1.4k 1.1×	747 1.5×	460 1.1×	177 0.5×	202 0.6×	40	3.4k

Countries citing papers authored by G. Pentheroudakis

Since Specialization

Citations

This map shows the geographic impact of G. Pentheroudakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Pentheroudakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Pentheroudakis more than expected).

Fields of papers citing papers by G. Pentheroudakis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Pentheroudakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Pentheroudakis. The network helps show where G. Pentheroudakis may publish in the future.

Co-authorship network of co-authors of G. Pentheroudakis

This figure shows the co-authorship network connecting the top 25 collaborators of G. Pentheroudakis. A scholar is included among the top collaborators of G. Pentheroudakis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Pentheroudakis. G. Pentheroudakis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oosting, Sjoukje F., Jorge Barriuso, Andrew Bottomley, et al.. (2022). Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. Annals of Oncology. 34(4). 431–439. 18 indexed citations

Yoshino, Takayuki, G. Pentheroudakis, Saori Mishima, et al.. (2020). JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Annals of Oncology. 31(7). 861–872. 83 indexed citations

Mauri, Davide, George Zarkavelis, Nikolaos P. Polyzos, et al.. (2019). Global coverage and consistency of guideline recommendations for cancer cachexia on the Web in 2011 and 2018. Współczesna Onkologia. 23(2). 100–109. 2 indexed citations

Gourzoulidis, George, Georgia Kourlaba, Dimitrios Petrakis, et al.. (2017). Economic Evaluation of Trifluridine and Tipiracil Hydrochloride in The Treatment of Metastatic Colorectal Cancer in Greece. Value in Health. 20(9). A434–A434. 1 indexed citations

Cherny, Nathan I., Urania Dafni, Jan Bogaerts, et al.. (2017). ESMO-Magnitude of Clinical Benefit Scale version 1.1. Annals of Oncology. 28(10). 2340–2366. 369 indexed citations breakdown →

Papakostas, Pavlos, et al.. (2014). Economic Evaluation of NAB-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for The Management of Metastatic Pancreatic Cancer in Greece. Value in Health. 17(7). A632–A632. 3 indexed citations

Peccatori, Fedro A., Hatem A. Azim, Roberto Orecchia, et al.. (2013). Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 24. vi160–vi170. 528 indexed citations breakdown →

Pentheroudakis, G., Vassiliki Kotoula, Elena Fountzilas, et al.. (2012). Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx. Oral Oncology. 48(8). 709–716. 14 indexed citations

Berruti, Alfredo, Eric Baudin, Hans Gelderblom, et al.. (2012). Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 23. vii131–vii138. 217 indexed citations

10.

Dummer, Reinhard, et al.. (2012). Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 23(12). vii86–vii91. 582 indexed citations breakdown →

11.

Voulgaris, Evangelos, G. Pentheroudakis, & Nicholas Pavlidis. (2011). Cancer and pregnancy: A comprehensive review. Surgical Oncology. 20(4). e175–e185. 71 indexed citations

12.

Pentheroudakis, G., Nikolaos Pavlidis, & M. Castiglione. (2009). Cancer, fertility and pregnancy: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology. 20. iv178–iv181. 12 indexed citations

13.

Pentheroudakis, G., Periklis Pappas, Vassilios Golfinopoulos, et al.. (2007). Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy. Cancer Chemotherapy and Pharmacology. 60(5). 733–739. 7 indexed citations

14.

Pentheroudakis, G., et al.. (2005). Phase I Trial of Intravenous Cisplatin-Topotecan Chemotherapy for Three Consecutive Days in Patients with Advanced Solid Tumors: Parallel Topotecan Escalation in Two Fixed Platinum Dosing Schemes. Chemotherapy. 51(2-3). 154–161. 2 indexed citations

15.

Pentheroudakis, G., George Fountzilas, Anna Kalogera‐Fountzila, et al.. (2004). Cavitating squamous cell lung carcinoma-distinct entity or not?. Lung Cancer. 45(3). 349–355. 24 indexed citations

16.

Pentheroudakis, G. & N. Pavlidis. (2004). Evidence-based Oncology. Annals of Oncology. 15(2). 361–361. 3 indexed citations

17.

Pentheroudakis, G., Jeff White, Jo Ann Davis, Iain Brown, & P. Vasey. (2003). Concurrent ovarian-type primary peritoneal adenocarcinoma and peritoneal choriocarcinoma. A case report and review of the literature. Gynecologic Oncology. 92(2). 697–700. 8 indexed citations

18.

Evans, T.R. Jeffry, G. Pentheroudakis, James Paul, et al.. (2002). A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Annals of Oncology. 13(9). 1469–1478. 46 indexed citations

19.

Pentheroudakis, G., V J O'Neill, P. Vasey, & S.B. Kaye. (2001). Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Supportive Care in Cancer. 9(7). 554–557. 41 indexed citations

20.

Gatzemeier, U., C.J. Twelves, Alan Anthoney, et al.. (2001). A phase I dose-escalation study of zd0473 combined with paclitaxel in refractory solid malignancies. European Journal of Cancer. 37. S74–S75. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact